ID   JAK3_HUMAN              Reviewed;        1124 AA.
AC   P52333; Q13259; Q13260; Q13611; Q8N1E8; Q99699; Q9Y6S2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Tyrosine-protein kinase JAK3;
DE            EC=2.7.10.2;
DE   AltName: Full=Janus kinase 3;
DE            Short=JAK-3;
DE   AltName: Full=Leukocyte janus kinase;
DE            Short=L-JAK;
GN   Name=JAK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8022790; DOI=10.1073/pnas.91.14.6374;
RA   Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.-Q.,
RA   Lal B.K., Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R.,
RA   O'Shea J.J.;
RT   "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase
RT   expressed in natural killer cells and activated leukocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6374-6378(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING
RP   (ISOFORM 2).
RX   PubMed=7559633; DOI=10.1074/jbc.270.42.25028;
RA   Lai K.S., Jin Y., Graham D.K., Witthuhn B.A., Ihle J.N., Liu E.T.;
RT   "A kinase-deficient splice variant of the human JAK3 is expressed in
RT   hematopoietic and epithelial cancer cells.";
RL   J. Biol. Chem. 270:25028-25036(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8921370; DOI=10.1006/geno.1996.0520;
RA   Riedy M.C., Dutra A.S., Blake T.B., Modi W., Lal B.K., Davis J.,
RA   Bosse A., O'Shea J.J., Johnston J.A.;
RT   "Genomic sequence, organization, and chromosomal localization of human
RT   JAK3.";
RL   Genomics 37:57-61(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-132 AND ILE-722.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-191.
RX   PubMed=8662778; DOI=10.1074/jbc.271.24.13976;
RA   Verbsky J.W., Bach E.A., Fang Y.F., Yang L., Randolph D.A.,
RA   Fields L.E.;
RT   "Expression of Janus kinase 3 in human endothelial and other non-
RT   lymphoid and non-myeloid cells.";
RL   J. Biol. Chem. 271:13976-13980(1996).
RN   [9]
RP   FUNCTION IN IL2 SIGNALING PATHWAY.
RX   PubMed=8022485; DOI=10.1038/370151a0;
RA   Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B.,
RA   Shibuya K., Ortaldo J.R., McVicar D.W., O'Shea J.J.;
RT   "Phosphorylation and activation of the Jak-3 Janus kinase in response
RT   to interleukin-2.";
RL   Nature 370:151-153(1994).
RN   [10]
RP   FUNCTION IN IL7 SIGNALING PATHWAY.
RX   PubMed=7662955;
RA   Sharfe N., Dadi H.K., Roifman C.M.;
RT   "JAK3 protein tyrosine kinase mediates interleukin-7-induced
RT   activation of phosphatidylinositol-3' kinase.";
RL   Blood 86:2077-2085(1995).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=7535338; DOI=10.1084/jem.181.4.1425;
RA   Musso T., Johnston J.A., Linnekin D., Varesio L., Rowe T.K.,
RA   O'Shea J.J., McVicar D.W.;
RT   "Regulation of JAK3 expression in human monocytes: phosphorylation in
RT   response to interleukins 2, 4, and 7.";
RL   J. Exp. Med. 181:1425-1431(1995).
RN   [12]
RP   INTERACTION WITH STAM2.
RC   TISSUE=Fetal brain;
RX   PubMed=10899310; DOI=10.1016/S0014-5793(00)01760-9;
RA   Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H.,
RA   Kikuchi K., Yamada M., Chenb M., O'Shea J.J., Sugamura K.;
RT   "STAM2, a new member of the STAM family, binding to the Janus
RT   kinases.";
RL   FEBS Lett. 477:55-61(2000).
RN   [13]
RP   INTERACTION WITH SHB.
RX   PubMed=12200137; DOI=10.1016/S0006-291X(02)02016-8;
RA   Lindholm C.K.;
RT   "IL-2 receptor signaling through the Shb adapter protein in T and NK
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 296:929-936(2002).
RN   [14]
RP   FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION
RP   AT TYR-980 AND TYR-981 BY PTPN2.
RX   PubMed=11909529; DOI=10.1016/S0960-9822(02)00697-8;
RA   Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.;
RT   "The T cell protein tyrosine phosphatase is a negative regulator of
RT   janus family kinases 1 and 3.";
RL   Curr. Biol. 12:446-453(2002).
RN   [15]
RP   DOMAIN.
RX   PubMed=12351625; DOI=10.1074/jbc.M205156200;
RA   Saharinen P., Silvennoinen O.;
RT   "The pseudokinase domain is required for suppression of basal activity
RT   of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible
RT   activation of signal transduction.";
RL   J. Biol. Chem. 277:47954-47963(2002).
RN   [16]
RP   PHOSPHORYLATION AT TYR-785, AND MUTAGENESIS OF TYR-785.
RX   PubMed=15121872; DOI=10.1128/MCB.24.10.4557-4570.2004;
RA   Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J.,
RA   Carter-Su C.;
RT   "Tyrosine 813 is a site of JAK2 autophosphorylation critical for
RT   activation of JAK2 by SH2-B beta.";
RL   Mol. Cell. Biol. 24:4557-4570(2004).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [18]
RP   PHOSPHORYLATION AT TYR-904 AND TYR-939, AND MUTAGENESIS OF LYS-855;
RP   TYR-904 AND TYR-939.
RX   PubMed=18250158; DOI=10.1128/MCB.01789-07;
RA   Cheng H., Ross J.A., Frost J.A., Kirken R.A.;
RT   "Phosphorylation of human Jak3 at tyrosines 904 and 939 positively
RT   regulates its activity.";
RL   Mol. Cell. Biol. 28:2271-2282(2008).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290934; DOI=10.1111/j.1600-065X.2008.00754.x;
RA   Ghoreschi K., Laurence A., O'Shea J.J.;
RT   "Janus kinases in immune cell signaling.";
RL   Immunol. Rev. 228:273-287(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   FUNCTION IN IL15 SIGNALING PATHWAY.
RX   PubMed=20440074; DOI=10.1172/JCI41344;
RA   Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S.,
RA   Dusanter-Fourt I., Verkarre V., Mention J.J., Rahmi G., Kiyono H.,
RA   Butz E.A., Brousse N., Cellier C., Cerf-Bensussan N., Meresse B.;
RT   "IL-15 triggers an antiapoptotic pathway in human intraepithelial
RT   lymphocytes that is a potential new target in celiac disease-
RT   associated inflammation and lymphomagenesis.";
RL   J. Clin. Invest. 120:2131-2143(2010).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 814-1103 IN COMPLEX WITH
RP   STAUROSPORINE ANALOG AFN941, AND PHOSPHORYLATION AT TYR-980 AND
RP   TYR-981.
RX   PubMed=15831699; DOI=10.1182/blood-2005-02-0707;
RA   Boggon T.J., Li Y., Manley P.W., Eck M.J.;
RT   "Crystal structure of the Jak3 kinase domain in complex with a
RT   staurosporine analog.";
RL   Blood 106:996-1002(2005).
RN   [24]
RP   VARIANT T(-)B(+)NK(-) SCID CYS-100.
RX   PubMed=7659163; DOI=10.1038/377065a0;
RA   Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F.,
RA   Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., Vezzoni P.,
RA   Notarangelo L.D.;
RT   "Mutations of Jak-3 gene in patients with autosomal severe combined
RT   immune deficiency (SCID).";
RL   Nature 377:65-68(1995).
RN   [25]
RP   VARIANTS T(-)B(+)NK(-) SCID GLY-481; 586-LEU--MET-592 DEL AND ARG-759.
RX   PubMed=9354668;
RA   Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F.,
RA   Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D.,
RA   Bozzi F., Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J.,
RA   Villa A.;
RT   "Structural and functional basis for JAK3-deficient severe combined
RT   immunodeficiency.";
RL   Blood 90:3996-4003(1997).
RN   [26]
RP   VARIANT T(-)B(+)NK(-) SCID TRP-582.
RX   PubMed=9753072; DOI=10.1111/j.1365-2141.1998.tb08990.x;
RA   Bozzi F., Lefranc G., Villa A., Badolato R., Schumacher R.F.,
RA   Khalil G., Loiselet J., Bresciani S., O'Shea J.J., Vezzoni P.,
RA   Notarangelo L.D., Candotti F.;
RT   "Molecular and biochemical characterization of JAK3 deficiency in a
RT   patient with severe combined immunodeficiency over 20 years after bone
RT   marrow transplantation: implications for treatment.";
RL   Br. J. Haematol. 102:1363-1366(1998).
RN   [27]
RP   VARIANTS T(-)B(+)NK(-) SCID ARG-151 AND SER-910, AND VARIANT ILE-722.
RX   PubMed=10982185; DOI=10.1007/s004390051012;
RA   Schumacher R.F., Mella P., Badolato R., Fiorini M., Savoldi G.,
RA   Giliani S., Villa A., Candotti F., Tampalini A., O'Shea J.J.,
RA   Notarangelo L.D.;
RT   "Complete genomic organization of the human JAK3 gene and mutation
RT   analysis in severe combined immunodeficiency by single-strand
RT   conformation polymorphism.";
RL   Hum. Genet. 106:73-79(2000).
RN   [28]
RP   VARIANTS T(-)B(+)NK(-) SCID ALA-58 DEL; GLU-169 AND SER-589, AND
RP   VARIANT ILE-722.
RX   PubMed=14615376; DOI=10.1182/blood-2003-06-2104;
RA   Roberts J.L., Lengi A., Brown S.M., Chen M., Zhou Y.-J., O'Shea J.J.,
RA   Buckley R.H.;
RT   "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and
RT   molecular analyses of 10 patients and outcomes of stem cell
RT   transplantation.";
RL   Blood 103:2009-2018(2004).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-12; HIS-40; THR-132; ARG-151;
RP   VAL-521; PRO-527; PHE-688 AND ILE-722.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine kinase involved in various
CC       processes such as cell growth, development, or differentiation.
CC       Mediates essential signaling events in both innate and adaptive
CC       immunity and plays a crucial role in hematopoiesis during T-cells
CC       development. In the cytoplasm, plays a pivotal role in signal
CC       transduction via its association with type I receptors sharing the
CC       common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and
CC       IL21R. Following ligand binding to cell surface receptors,
CC       phosphorylates specific tyrosine residues on the cytoplasmic tails
CC       of the receptor, creating docking sites for STATs proteins.
CC       Subsequently, phosphorylates the STATs proteins once they are
CC       recruited to the receptor. Phosphorylated STATs then form
CC       homodimer or heterodimers and translocate to the nucleus to
CC       activate gene transcription. For example, upon IL2R activation by
CC       IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma
CC       chain (IL2RG) subunits inducing the tyrosine phosphorylation of
CC       both receptor subunits on their cytoplasmic domain. Then, STAT5A
CC       AND STAT5B are recruited, phosphorylated and activated by JAK1 and
CC       JAK3. Once activated, dimerized STAT5 translocates to the nucleus
CC       and promotes the transcription of specific target genes in a
CC       cytokine-specific fashion. {ECO:0000269|PubMed:11909529,
CC       ECO:0000269|PubMed:20440074, ECO:0000269|PubMed:7662955,
CC       ECO:0000269|PubMed:8022485}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Interacts with STAM2 and MYO18A (By similarity).
CC       Interacts with SHB. {ECO:0000250, ECO:0000269|PubMed:10899310,
CC       ECO:0000269|PubMed:12200137, ECO:0000269|PubMed:15831699}.
CC   -!- INTERACTION:
CC       Q07666:KHDRBS1; NbExp=2; IntAct=EBI-518246, EBI-1364;
CC       Q9UNF1:MAGED2; NbExp=3; IntAct=EBI-518246, EBI-725832;
CC       P55209:NAP1L1; NbExp=3; IntAct=EBI-518246, EBI-356392;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2; Synonyms=JAK3S, Spleen-JAK3;
CC         IsoId=P52333-1; Sequence=Displayed;
CC       Name=1; Synonyms=JAK3B, Breast-JAK3;
CC         IsoId=P52333-2; Sequence=VSP_004989;
CC         Note=May be inactive as it lacks some part of the kinase
CC         domain.;
CC       Name=3;
CC         IsoId=P52333-4; Sequence=VSP_054165, VSP_054166;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: In NK cells and an NK-like cell line but not
CC       in resting T-cells or in other tissues. The S-form is more
CC       commonly seen in hematopoietic lines, whereas the B-form is
CC       detected in cells both of hematopoietic and epithelial origins.
CC       {ECO:0000269|PubMed:7535338}.
CC   -!- DOMAIN: Possesses two phosphotransferase domains. The second one
CC       probably contains the catalytic domain (By similarity), while the
CC       presence of slight differences suggest a different role for domain
CC       1. {ECO:0000250, ECO:0000269|PubMed:12351625}.
CC   -!- PTM: Tyrosine phosphorylated in response to IL-2 and IL-4.
CC       Dephosphorylation of Tyr-980 and Tyr-981 by PTPN2 negatively
CC       regulates cytokine-mediated signaling (Probable).
CC       {ECO:0000305|PubMed:11909529, ECO:0000305|PubMed:15121872,
CC       ECO:0000305|PubMed:15831699, ECO:0000305|PubMed:18250158}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-
CC       cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)
CC       SCID) [MIM:600802]: A form of severe combined immunodeficiency
CC       (SCID), a genetically and clinically heterogeneous group of rare
CC       congenital disorders characterized by impairment of both humoral
CC       and cell-mediated immunity, leukopenia, and low or absent antibody
CC       levels. Patients present in infancy recurrent, persistent
CC       infections by opportunistic organisms. The common characteristic
CC       of all types of SCID is absence of T-cell-mediated cellular
CC       immunity due to a defect in T-cell development.
CC       {ECO:0000269|PubMed:10982185, ECO:0000269|PubMed:14615376,
CC       ECO:0000269|PubMed:7659163, ECO:0000269|PubMed:9354668,
CC       ECO:0000269|PubMed:9753072}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50227.1; Type=Miscellaneous discrepancy; Note=Wrong choice of CDS. Was erroneously described as an isoform JAK3M while it is a fragmentary mRNA of INSL3.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAK3ID41032ch19p13.html";
CC   -!- WEB RESOURCE: Name=JAK3base; Note=JAK3 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/JAK3base/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/jak3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U09607; AAA19626.1; -; mRNA.
DR   EMBL; U31601; AAC50226.1; -; mRNA.
DR   EMBL; U31602; AAC50227.1; ALT_SEQ; mRNA.
DR   EMBL; U70065; AAC50950.1; -; Genomic_DNA.
DR   EMBL; AF513860; AAM44860.1; -; Genomic_DNA.
DR   EMBL; AC007201; AAD22741.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84639.1; -; Genomic_DNA.
DR   EMBL; BC028068; AAH28068.1; -; mRNA.
DR   EMBL; U57096; AAC50542.1; -; mRNA.
DR   CCDS; CCDS12366.1; -. [P52333-1]
DR   PIR; A55747; A55747.
DR   RefSeq; NP_000206.2; NM_000215.3. [P52333-1]
DR   UniGene; Hs.515247; -.
DR   PDB; 1YVJ; X-ray; 2.55 A; A=814-1103.
DR   PDB; 3LXK; X-ray; 2.00 A; A=806-1124.
DR   PDB; 3LXL; X-ray; 1.74 A; A=806-1124.
DR   PDB; 3PJC; X-ray; 2.20 A; A=812-1124.
DR   PDB; 3ZC6; X-ray; 2.42 A; A/B/C/D=813-1100.
DR   PDB; 3ZEP; X-ray; 2.35 A; A/B/C/D=813-1047, A/B/C/D=813-1100.
DR   PDB; 4HVD; X-ray; 1.85 A; A=811-1124.
DR   PDB; 4HVG; X-ray; 2.75 A; A=811-1124.
DR   PDB; 4HVH; X-ray; 2.30 A; A=811-1124.
DR   PDB; 4HVI; X-ray; 2.40 A; A=811-1124.
DR   PDB; 4I6Q; X-ray; 1.85 A; A=811-1124.
DR   PDB; 4QPS; X-ray; 1.80 A; A/C=811-1103.
DR   PDB; 4QT1; X-ray; 2.40 A; A=811-1124.
DR   PDB; 4RIO; X-ray; 2.69 A; A=810-1100.
DR   PDB; 4V0G; X-ray; 3.00 A; A/B=816-1098.
DR   PDB; 4Z16; X-ray; 2.90 A; A/B/C/D=811-1124.
DR   PDB; 5LWM; X-ray; 1.55 A; A=812-1103.
DR   PDB; 5LWN; X-ray; 1.60 A; A=812-1103.
DR   PDB; 5TOZ; X-ray; 1.98 A; A=812-1124.
DR   PDB; 5TTS; X-ray; 2.34 A; A=812-1124.
DR   PDB; 5TTU; X-ray; 1.72 A; A=812-1124.
DR   PDB; 5TTV; X-ray; 1.93 A; A=812-1124.
DR   PDBsum; 1YVJ; -.
DR   PDBsum; 3LXK; -.
DR   PDBsum; 3LXL; -.
DR   PDBsum; 3PJC; -.
DR   PDBsum; 3ZC6; -.
DR   PDBsum; 3ZEP; -.
DR   PDBsum; 4HVD; -.
DR   PDBsum; 4HVG; -.
DR   PDBsum; 4HVH; -.
DR   PDBsum; 4HVI; -.
DR   PDBsum; 4I6Q; -.
DR   PDBsum; 4QPS; -.
DR   PDBsum; 4QT1; -.
DR   PDBsum; 4RIO; -.
DR   PDBsum; 4V0G; -.
DR   PDBsum; 4Z16; -.
DR   PDBsum; 5LWM; -.
DR   PDBsum; 5LWN; -.
DR   PDBsum; 5TOZ; -.
DR   PDBsum; 5TTS; -.
DR   PDBsum; 5TTU; -.
DR   PDBsum; 5TTV; -.
DR   ProteinModelPortal; P52333; -.
DR   SMR; P52333; -.
DR   BioGrid; 109921; 73.
DR   DIP; DIP-274N; -.
DR   IntAct; P52333; 50.
DR   MINT; MINT-1497014; -.
DR   STRING; 9606.ENSP00000391676; -.
DR   BindingDB; P52333; -.
DR   ChEMBL; CHEMBL2148; -.
DR   DrugBank; DB08895; Tofacitinib.
DR   GuidetoPHARMACOLOGY; 2049; -.
DR   iPTMnet; P52333; -.
DR   PhosphoSitePlus; P52333; -.
DR   BioMuta; JAK3; -.
DR   DMDM; 50403745; -.
DR   MaxQB; P52333; -.
DR   PaxDb; P52333; -.
DR   PeptideAtlas; P52333; -.
DR   PRIDE; P52333; -.
DR   DNASU; 3718; -.
DR   Ensembl; ENST00000458235; ENSP00000391676; ENSG00000105639. [P52333-1]
DR   Ensembl; ENST00000527670; ENSP00000432511; ENSG00000105639. [P52333-1]
DR   Ensembl; ENST00000534444; ENSP00000436421; ENSG00000105639. [P52333-2]
DR   GeneID; 3718; -.
DR   KEGG; hsa:3718; -.
DR   UCSC; uc002nhn.5; human. [P52333-1]
DR   CTD; 3718; -.
DR   DisGeNET; 3718; -.
DR   GeneCards; JAK3; -.
DR   HGNC; HGNC:6193; JAK3.
DR   HPA; HPA070314; -.
DR   MalaCards; JAK3; -.
DR   MIM; 600173; gene.
DR   MIM; 600802; phenotype.
DR   neXtProt; NX_P52333; -.
DR   OpenTargets; ENSG00000105639; -.
DR   Orphanet; 35078; T-B+ severe combined immunodeficiency due to JAK3 deficiency.
DR   PharmGKB; PA29990; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000049158; -.
DR   HOVERGEN; HBG006195; -.
DR   InParanoid; P52333; -.
DR   KO; K11218; -.
DR   OMA; IAWTQGE; -.
DR   OrthoDB; EOG091G01IS; -.
DR   PhylomeDB; P52333; -.
DR   TreeFam; TF327041; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-451927; Interleukin-2 signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   SignaLink; P52333; -.
DR   SIGNOR; P52333; -.
DR   EvolutionaryTrace; P52333; -.
DR   GeneWiki; Janus_kinase_3; -.
DR   GenomeRNAi; 3718; -.
DR   PRO; PR:P52333; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105639; -.
DR   CleanEx; HS_JAK3; -.
DR   ExpressionAtlas; P52333; baseline and differential.
DR   Genevisible; P52333; HS.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:BHF-UCL.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007167; P:enzyme linked receptor protein signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030218; P:erythrocyte differentiation; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035771; P:interleukin-4-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0002731; P:negative regulation of dendritic cell cytokine production; ISS:BHF-UCL.
DR   GO; GO:0045221; P:negative regulation of FasL biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; ISS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0050868; P:negative regulation of T cell activation; ISS:BHF-UCL.
DR   GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0070232; P:regulation of T cell apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0070672; P:response to interleukin-15; TAS:BHF-UCL.
DR   GO; GO:0070669; P:response to interleukin-2; TAS:BHF-UCL.
DR   GO; GO:0070670; P:response to interleukin-4; IDA:BHF-UCL.
DR   GO; GO:0071104; P:response to interleukin-9; TAS:BHF-UCL.
DR   GO; GO:0007262; P:STAT protein import into nucleus; TAS:UniProtKB.
DR   GO; GO:0043029; P:T cell homeostasis; ISS:BHF-UCL.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; TAS:UniProtKB.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020775; Tyr_kinase_non-rcpt_Jak3.
DR   Pfam; PF07714; Pkinase_Tyr; 2.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01826; JANUSKINASE3.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Disease mutation; Immunity;
KW   Innate immunity; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; SCID; SH2 domain;
KW   Transferase; Tyrosine-protein kinase.
FT   CHAIN         1   1124       Tyrosine-protein kinase JAK3.
FT                                /FTId=PRO_0000088115.
FT   DOMAIN       24    356       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN      375    475       SH2; atypical.
FT   DOMAIN      521    781       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      822   1111       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     828    836       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    223       Interaction with
FT                                cytokine/interferon/growth hormone
FT                                receptors. {ECO:0000250}.
FT   ACT_SITE    949    949       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     855    855       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      17     17       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62137}.
FT   MOD_RES     785    785       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15121872}.
FT   MOD_RES     904    904       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18250158}.
FT   MOD_RES     939    939       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18250158}.
FT   MOD_RES     980    980       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15831699}.
FT   MOD_RES     981    981       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15831699}.
FT   VAR_SEQ     597    619       TMVQEFVHLGAIDMYLRKRGHLV -> ESPPPTHPTPASPK
FT                                SRLFFPPLF (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054165.
FT   VAR_SEQ     620   1124       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054166.
FT   VAR_SEQ    1071   1124       HELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFT
FT                                AHPEGKHHSLSFS -> SAAGLASVSQSVDWAGVSGKPAGA
FT                                (in isoform 1).
FT                                {ECO:0000303|PubMed:7559633}.
FT                                /FTId=VSP_004989.
FT   VARIANT      12     12       P -> L (in dbSNP:rs56061056).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041722.
FT   VARIANT      40     40       R -> H (in dbSNP:rs56384680).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041723.
FT   VARIANT      58     58       Missing (in T(-)B(+)NK(-) SCID).
FT                                {ECO:0000269|PubMed:14615376}.
FT                                /FTId=VAR_019337.
FT   VARIANT     100    100       Y -> C (in T(-)B(+)NK(-) SCID;
FT                                dbSNP:rs137852624).
FT                                {ECO:0000269|PubMed:7659163}.
FT                                /FTId=VAR_006284.
FT   VARIANT     132    132       P -> T (in dbSNP:rs3212723).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019336.
FT   VARIANT     151    151       P -> R (in T(-)B(+)NK(-) SCID;
FT                                dbSNP:rs55778349).
FT                                {ECO:0000269|PubMed:10982185,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_010492.
FT   VARIANT     169    169       D -> E (in T(-)B(+)NK(-) SCID;
FT                                dbSNP:rs147181709).
FT                                {ECO:0000269|PubMed:14615376}.
FT                                /FTId=VAR_019338.
FT   VARIANT     481    481       E -> G (in T(-)B(+)NK(-) SCID).
FT                                {ECO:0000269|PubMed:9354668}.
FT                                /FTId=VAR_010493.
FT   VARIANT     521    521       L -> V (in dbSNP:rs55666418).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041724.
FT   VARIANT     527    527       L -> P (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041725.
FT   VARIANT     582    582       R -> W (in T(-)B(+)NK(-) SCID;
FT                                dbSNP:rs193922361).
FT                                {ECO:0000269|PubMed:9753072}.
FT                                /FTId=VAR_010494.
FT   VARIANT     586    592       Missing (in T(-)B(+)NK(-) SCID; lack of
FT                                phosphorylation in response to cytokine
FT                                stimulation).
FT                                {ECO:0000269|PubMed:9354668}.
FT                                /FTId=VAR_010495.
FT   VARIANT     589    589       G -> S (in T(-)B(+)NK(-) SCID).
FT                                {ECO:0000269|PubMed:14615376}.
FT                                /FTId=VAR_019339.
FT   VARIANT     688    688       I -> F (in dbSNP:rs35785705).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041726.
FT   VARIANT     722    722       V -> I (in dbSNP:rs3213409).
FT                                {ECO:0000269|PubMed:10982185,
FT                                ECO:0000269|PubMed:14615376,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_010496.
FT   VARIANT     759    759       C -> R (in T(-)B(+)NK(-) SCID;
FT                                constitutive phosphorylation).
FT                                {ECO:0000269|PubMed:9354668}.
FT                                /FTId=VAR_010497.
FT   VARIANT     910    910       L -> S (in T(-)B(+)NK(-) SCID).
FT                                {ECO:0000269|PubMed:10982185}.
FT                                /FTId=VAR_010498.
FT   MUTAGEN     785    785       Y->F: Strong decrease of JAK3
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:15121872}.
FT   MUTAGEN     855    855       K->A: More than 90% loss of STAT5a
FT                                activation.
FT                                {ECO:0000269|PubMed:18250158}.
FT   MUTAGEN     904    904       Y->F: About 40% loss of STAT5a
FT                                activation.
FT                                {ECO:0000269|PubMed:18250158}.
FT   MUTAGEN     939    939       Y->F: About 80% loss of STAT5a
FT                                activation.
FT                                {ECO:0000269|PubMed:18250158}.
FT   CONFLICT     34     34       G -> A (in Ref. 1; AAA19626).
FT                                {ECO:0000305}.
FT   CONFLICT     45     45       F -> S (in Ref. 3; AAC50950).
FT                                {ECO:0000305}.
FT   CONFLICT    103    103       R -> RS (in Ref. 3; AAC50950).
FT                                {ECO:0000305}.
FT   CONFLICT    147    147       Missing (in Ref. 8; AAC50542).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       T -> A (in Ref. 8; AAC50542).
FT                                {ECO:0000305}.
FT   CONFLICT    212    212       R -> A (in Ref. 1; AAA19626 and 3;
FT                                AAC50950). {ECO:0000305}.
FT   CONFLICT    222    222       R -> P (in Ref. 1; AAA19626 and 3;
FT                                AAC50950). {ECO:0000305}.
FT   CONFLICT    271    271       L -> F (in Ref. 3; AAC50950).
FT                                {ECO:0000305}.
FT   CONFLICT    287    287       Missing (in Ref. 3; AAC50950).
FT                                {ECO:0000305}.
FT   CONFLICT    610    610       M -> I (in Ref. 2; AAC50226).
FT                                {ECO:0000305}.
FT   CONFLICT    845    846       GD -> AH (in Ref. 1; AAA19626).
FT                                {ECO:0000305}.
FT   CONFLICT    895    897       RQS -> EPE (in Ref. 3; AAC50950).
FT                                {ECO:0000305}.
FT   CONFLICT    896    897       QS -> PE (in Ref. 1; AAA19626).
FT                                {ECO:0000305}.
FT   STRAND      816    818       {ECO:0000244|PDB:5LWM}.
FT   HELIX       819    821       {ECO:0000244|PDB:5LWM}.
FT   STRAND      822    830       {ECO:0000244|PDB:5LWM}.
FT   STRAND      832    841       {ECO:0000244|PDB:5LWM}.
FT   STRAND      845    847       {ECO:0000244|PDB:5LWM}.
FT   STRAND      849    859       {ECO:0000244|PDB:5LWM}.
FT   HELIX       862    877       {ECO:0000244|PDB:5LWM}.
FT   STRAND      886    891       {ECO:0000244|PDB:5LWM}.
FT   STRAND      893    896       {ECO:0000244|PDB:5LWM}.
FT   STRAND      898    903       {ECO:0000244|PDB:5LWM}.
FT   HELIX       910    917       {ECO:0000244|PDB:5LWM}.
FT   HELIX       918    920       {ECO:0000244|PDB:5LWM}.
FT   HELIX       923    942       {ECO:0000244|PDB:5LWM}.
FT   HELIX       952    954       {ECO:0000244|PDB:5LWM}.
FT   STRAND      955    959       {ECO:0000244|PDB:5LWM}.
FT   STRAND      962    965       {ECO:0000244|PDB:5LWM}.
FT   HELIX       968    970       {ECO:0000244|PDB:3LXL}.
FT   STRAND      979    982       {ECO:0000244|PDB:5LWM}.
FT   HELIX       991    993       {ECO:0000244|PDB:5LWM}.
FT   HELIX       996   1001       {ECO:0000244|PDB:5LWM}.
FT   STRAND     1003   1005       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1006   1021       {ECO:0000244|PDB:5LWM}.
FT   TURN       1022   1024       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1026   1028       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1030   1037       {ECO:0000244|PDB:5LWM}.
FT   STRAND     1042   1044       {ECO:0000244|PDB:4QPS}.
FT   HELIX      1046   1055       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1068   1077       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1082   1084       {ECO:0000244|PDB:5LWM}.
FT   HELIX      1088   1102       {ECO:0000244|PDB:5LWM}.
SQ   SEQUENCE   1124 AA;  125099 MW;  895D8563439B2B7C CRC64;
     MAPPSEETPL IPQRSCSLLS TEAGALHVLL PARGPGPPQR LSFSFGDHLA EDLCVQAAKA
     SGILPVYHSL FALATEDLSC WFPPSHIFSV EDASTQVLLY RIRFYFPNWF GLEKCHRFGL
     RKDLASAILD LPVLEHLFAQ HRSDLVSGRL PVGLSLKEQG ECLSLAVLDL ARMAREQAQR
     PGELLKTVSY KACLPPSLRD LIQGLSFVTR RRIRRTVRRA LRRVAACQAD RHSLMAKYIM
     DLERLDPAGA AETFHVGLPG ALGGHDGLGL LRVAGDGGIA WTQGEQEVLQ PFCDFPEIVD
     ISIKQAPRVG PAGEHRLVTV TRTDNQILEA EFPGLPEALS FVALVDGYFR LTTDSQHFFC
     KEVAPPRLLE EVAEQCHGPI TLDFAINKLK TGGSRPGSYV LRRSPQDFDS FLLTVCVQNP
     LGPDYKGCLI RRSPTGTFLL VGLSRPHSSL RELLATCWDG GLHVDGVAVT LTSCCIPRPK
     EKSNLIVVQR GHSPPTSSLV QPQSQYQLSQ MTFHKIPADS LEWHENLGHG SFTKIYRGCR
     HEVVDGEARK TEVLLKVMDA KHKNCMESFL EAASLMSQVS YRHLVLLHGV CMAGDSTMVQ
     EFVHLGAIDM YLRKRGHLVP ASWKLQVVKQ LAYALNYLED KGLPHGNVSA RKVLLAREGA
     DGSPPFIKLS DPGVSPAVLS LEMLTDRIPW VAPECLREAQ TLSLEADKWG FGATVWEVFS
     GVTMPISALD PAKKLQFYED RQQLPAPKWT ELALLIQQCM AYEPVQRPSF RAVIRDLNSL
     ISSDYELLSD PTPGALAPRD GLWNGAQLYA CQDPTIFEER HLKYISQLGK GNFGSVELCR
     YDPLGDNTGA LVAVKQLQHS GPDQQRDFQR EIQILKALHS DFIVKYRGVS YGPGRQSLRL
     VMEYLPSGCL RDFLQRHRAR LDASRLLLYS SQICKGMEYL GSRRCVHRDL AARNILVESE
     AHVKIADFGL AKLLPLDKDY YVVREPGQSP IFWYAPESLS DNIFSRQSDV WSFGVVLYEL
     FTYCDKSCSP SAEFLRMMGC ERDVPALCRL LELLEEGQRL PAPPACPAEV HELMKLCWAP
     SPQDRPSFSA LGPQLDMLWS GSRGCETHAF TAHPEGKHHS LSFS
//
